Skip to main content
Top
Published in: Journal of Gastroenterology 1/2010

01-01-2010 | Original Article—Liver, Pancreas, and Biliary Tract

Etiology of liver cirrhosis in Japan: a nationwide survey

Authors: Kojiro Michitaka, Shuhei Nishiguchi, Yutaka Aoyagi, Yoichi Hiasa, Yoshio Tokumoto, Morikazu Onji, The Japan Etiology of Liver Cirrhosis Study Group

Published in: Journal of Gastroenterology | Issue 1/2010

Login to get access

Abstract

Background

Little is understood about worldwide changes in the epidemiological distribution of the etiology of liver cirrhosis (LC). The present study examines the etiology of liver cirrhosis in Japan using a nationwide survey.

Methods

We analyzed data from 33,379 patients with LC at 58 hospitals and presented the findings in a poster symposium regarding the etiology and clinical features of LC in Japan that was included in the program of the 44th Annual Meeting of the Japan Society of Hepatology. We identified the distribution of the etiology of LC and compared the present with previous Japanese findings to estimate the future of etiological changes in LC.

Results

The etiological agents were as follows: hepatitis B virus (HBV) 13.9%, hepatitis C virus (HCV) 60.9%, alcohol 13.6%, primary biliary cirrhosis (PBC) 2.4% and autoimmune hepatitis (AIH) 1.9%. Cirrhosis was considered to be related to nonalcoholic steatohepatitis (NASH) in 2.1% of the patients. The ratio of HCV-related LC was significantly higher among patients with hepatocellular carcinoma (HCC) (P < 0.0001) compared to those without, whereas the ratios of alcohol, PBC, AIH were lower. HCC was evident in 31.5% of NASH-related LC.

Conclusions

The major etiology of liver cirrhosis in Japan remains HCV. Our survey revealed the prevalence of NASH-related LC in Japan and the frequency of HCC. Future changes in etiology must be considered in establishing preventive or educational strategies, as well as in developing new treatment strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.CrossRefPubMed Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38.CrossRefPubMed
2.
go back to reference Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25:3771–7.CrossRefPubMed Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25:3771–7.CrossRefPubMed
3.
go back to reference Manos MM, Leyden WA, Murphy RC, Terrault NA, Bell BP. Limitation of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology. 2008;47:1150–7.CrossRefPubMed Manos MM, Leyden WA, Murphy RC, Terrault NA, Bell BP. Limitation of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology. 2008;47:1150–7.CrossRefPubMed
4.
go back to reference Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol. 2008;103:2727–36.CrossRefPubMed Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol. 2008;103:2727–36.CrossRefPubMed
5.
go back to reference Fleming KM, Aithat GP, Solaymani-Dodaran M, Card M, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001: a general population-based study. J Hepatol. 2008;49:732–8.CrossRefPubMed Fleming KM, Aithat GP, Solaymani-Dodaran M, Card M, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001: a general population-based study. J Hepatol. 2008;49:732–8.CrossRefPubMed
6.
go back to reference Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349–54.PubMed Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349–54.PubMed
7.
go back to reference Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–40.CrossRefPubMed Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–40.CrossRefPubMed
8.
go back to reference Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485–93.CrossRefPubMed Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485–93.CrossRefPubMed
9.
go back to reference Harrison AS, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98:2042–7.CrossRefPubMed Harrison AS, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98:2042–7.CrossRefPubMed
10.
go back to reference Takada A, Tsutsumi M. National survey of alcoholic liver disease in Japan (1968–1991). J Gastroenterol Hepatol. 1995;10:509–16.CrossRefPubMed Takada A, Tsutsumi M. National survey of alcoholic liver disease in Japan (1968–1991). J Gastroenterol Hepatol. 1995;10:509–16.CrossRefPubMed
11.
go back to reference Tanaka Y, Kurbanov F, Mano S, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006;130:703–14.CrossRefPubMed Tanaka Y, Kurbanov F, Mano S, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006;130:703–14.CrossRefPubMed
12.
go back to reference Willcox BJ, Willcox DC, Todoriki H, et al. Caloric restriction, the traditional Okinawan diet, and healthy aging: the diet of the world’s longest-lived people and its potential impact on morbidity and life span. Ann N Y Acad Sci. 2007;1114:434–55.CrossRefPubMed Willcox BJ, Willcox DC, Todoriki H, et al. Caloric restriction, the traditional Okinawan diet, and healthy aging: the diet of the world’s longest-lived people and its potential impact on morbidity and life span. Ann N Y Acad Sci. 2007;1114:434–55.CrossRefPubMed
13.
go back to reference Okamoto K. Life expectancy at the age of 65 years and environmental factors: an ecological study in Japan. Arch Gerontol Geriatr. 2006;43:85–91.CrossRefPubMed Okamoto K. Life expectancy at the age of 65 years and environmental factors: an ecological study in Japan. Arch Gerontol Geriatr. 2006;43:85–91.CrossRefPubMed
14.
go back to reference Tanaka J, Mizui M, Nagakami H, Katayama K, Tabuchi A, Komiya Y, et al. Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004. Intervirology. 2008;51:33–41.CrossRefPubMed Tanaka J, Mizui M, Nagakami H, Katayama K, Tabuchi A, Komiya Y, et al. Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004. Intervirology. 2008;51:33–41.CrossRefPubMed
15.
go back to reference Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995–2000. Intervirology. 2004;47:32–40.CrossRefPubMed Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995–2000. Intervirology. 2004;47:32–40.CrossRefPubMed
16.
go back to reference Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676–91.CrossRefPubMed Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676–91.CrossRefPubMed
17.
go back to reference Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.CrossRefPubMed Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.CrossRefPubMed
18.
go back to reference Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.CrossRefPubMed Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.CrossRefPubMed
19.
go back to reference Patel A, Huang KC, Janus ED, Gill T, Neal B, Suriyawongpaisal P, et al. Is a single definition of the metabolic syndrome appropriate?—A comparative study of the USA and Asia. Atherosclerosis. 2006;184:225–32.CrossRefPubMed Patel A, Huang KC, Janus ED, Gill T, Neal B, Suriyawongpaisal P, et al. Is a single definition of the metabolic syndrome appropriate?—A comparative study of the USA and Asia. Atherosclerosis. 2006;184:225–32.CrossRefPubMed
20.
go back to reference Ninomiya T, Kubo M, Doi Y, Yonemoto K, Tanizaki Y, Rahman M, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. Stroke. 2007;38:2063–9.CrossRefPubMed Ninomiya T, Kubo M, Doi Y, Yonemoto K, Tanizaki Y, Rahman M, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. Stroke. 2007;38:2063–9.CrossRefPubMed
21.
go back to reference Yoshiike N, Lwin H. Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol Res. 2005;33:77–82.CrossRefPubMed Yoshiike N, Lwin H. Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol Res. 2005;33:77–82.CrossRefPubMed
22.
go back to reference Fujino Y, Mizoue T, Tokui N, Yoshimura T. Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev. 2001;17:374–9.CrossRefPubMed Fujino Y, Mizoue T, Tokui N, Yoshimura T. Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev. 2001;17:374–9.CrossRefPubMed
23.
go back to reference Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2008;24:248–54.CrossRefPubMed Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2008;24:248–54.CrossRefPubMed
24.
go back to reference Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485–93.CrossRefPubMed Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485–93.CrossRefPubMed
25.
go back to reference Chan HL, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS, et al. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol. 2002;97:1211–5.CrossRefPubMed Chan HL, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS, et al. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol. 2002;97:1211–5.CrossRefPubMed
Metadata
Title
Etiology of liver cirrhosis in Japan: a nationwide survey
Authors
Kojiro Michitaka
Shuhei Nishiguchi
Yutaka Aoyagi
Yoichi Hiasa
Yoshio Tokumoto
Morikazu Onji
The Japan Etiology of Liver Cirrhosis Study Group
Publication date
01-01-2010
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2010
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0128-5

Other articles of this Issue 1/2010

Journal of Gastroenterology 1/2010 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

Identification and location of label retaining cells in mouse liver

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.